NeOnc Breaksthrough Brain Cancer Treatment #newsout #healthcareinnovation #biotechinvesting #biotech

Apr 7, 2026

For biotech investors, medical innovators, and healthcare technology audiences — this New to The Street interview from the New York Stock Exchange features Amir Heshmatpour, CEO of NeOnc Technologies, discussing a groundbreaking approach to treating aggressive brain cancers using intranasal drug delivery.

NeOnc has developed the first platform that delivers chemotherapy directly to brain tumors through the nasal cavity, bypassing the blood–brain barrier and dramatically reducing systemic toxicity. Built on 179 global patents from USC Keck Medical School, the company is currently running four clinical trials, including three Phase II studies and a pediatric Phase I trial.

See full interview here: https://youtu.be/GWUFyJMtyiI